ZEAL
Zealand Pharma A/S
Set alert
52-week range unavailable
- Open
- 18.03
- Prev close
- 17.59
- Mkt cap
- 814.14M
- Vol
- 2.16K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 17.47
- High
- 18.07
- Forward P/E
- -6.49
- Beta
- 1.34
- Short ratio
- 37.96
- Inst. own
- 1.75%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 10, 2022
- 50-d avg
- 17.73
- 200-d avg
- 15.57
- 1y target
- 32.30
Key statistics
- Market cap
- 814.14M
- Enterprise value
- 434.86M
- Trailing P/E
- 0.00
- Forward P/E
- -6.49
- PEG ratio
- 0.00
- Price / sales
- 2.77
- Price / book
- 1.61
- EPS (TTM)
- -3.26
- Beta
- 1.34
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 293.77M
- Revenue growth
- -22.40%
- Free cash flow
- -505.17M
- Total cash
- 864.44M
- Total debt
- 485.42M
- Return on equity
- -115.45%
- Shares outstanding
- 46.12M
- Short % of float
- 0.00%
- 50-day average
- 17.73
- 200-day average
- 15.57
Analyst view
Consensus: buy
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 10, 2022
Expected Nov 10, 2022. Consensus EPS estimate -0.71.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 10, 2022 | Sep 1, 2022 | -0.83 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -1.53 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -1.01 | — | — | — |
| Mar 10, 2022 | Dec 1, 2021 | -1.07 | — | — | — |
| Nov 11, 2021 | Sep 1, 2021 | -1.13 | — | — | — |
| Aug 12, 2021 | Jun 1, 2021 | -0.93 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 13, 2022 | Needham | main | — | Buy |
| Nov 13, 2020 | Morgan Stanley | main | — | Overweight |
| Oct 13, 2020 | Morgan Stanley | main | — | Overweight |
| Aug 14, 2020 | Morgan Stanley | main | — | Overweight |
| Apr 15, 2020 | Morgan Stanley | main | — | Overweight |
| Mar 31, 2020 | Morgan Stanley | main | — | Overweight |
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- Website
- zealandpharma.com
News
- Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830
- Generate Biomedicines To Receive $30M Upfront, Up To $1.2B In Milestones And Tiered Royalties Under Zealand Pharma Collaboration
- Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
- Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes
- Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)
- Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts
- Zealand Pharma announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
- Total number of shares and voting rights in Zealand Pharma as of September 30, 2026
- Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
- Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)
Your note
Sign in to keep a note on ZEAL — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Goldman Sachs Group Inc | 1.08% | 500,916 | 8.81M | Jun 29, 2022 |
| Farallon Capital Management Llc | 1.07% | 496,890 | 8.74M | Mar 30, 2022 |
| Bank of America Corporation | 0.47% | 220,523 | 3.88M | Jun 29, 2022 |
| AWM Investment Company, Inc. | 0.11% | 48,957 | 861.15K | Jun 29, 2022 |
| Jane Street Group, LLC | 0.05% | 23,976 | 421.74K | Jun 29, 2022 |
| Morgan Stanley | 0.01% | 6,705 | 117.94K | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) International Discovery Fund | 2.85% | 1,326,807 | 23.34M | Mar 30, 2022 |
| iShares Core MSCI EAFE ETF | 0.43% | 200,193 | 3.52M | Aug 30, 2022 |
| iShares MSCI EAFE Small Cap ETF | 0.32% | 148,974 | 2.62M | Aug 30, 2022 |
| iShares Core MSCI Total International Stock ETF | 0.14% | 66,909 | 1.18M | Aug 30, 2022 |
| iShares MSCI Denmark ETF | 0.13% | 59,501 | 1.05M | Aug 30, 2022 |
| Hartford Healthcare Fund | 0.12% | 57,750 | 1.02M | Jan 30, 2022 |